Literature DB >> 5418176

The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.

G Curzon, R B Godwin-Austen, E B Tomlinson, B D Kantamaneni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5418176      PMCID： PMC493400          DOI： 10.1136/jnnp.33.1.1

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  19 in total

1.  On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method.

Authors:  N E ANDEN; B E ROOS; B WERDINIUS
Journal:  Life Sci (1962)       Date:  1963-07

2.  INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM.

Authors:  L J POIRIER; T L SOURKES
Journal:  Brain       Date:  1965-03       Impact factor: 13.501

3.  The brain-stem lesions in Parkinsonism.

Authors:  J G GREENFIELD; F D BOSANQUET
Journal:  J Neurol Neurosurg Psychiatry       Date:  1953-11       Impact factor: 10.154

4.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

5.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

6.  Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease.

Authors:  R Olsson; B E Roos
Journal:  Nature       Date:  1968-08-03       Impact factor: 49.962

7.  Acceleration of the cerebral dopamine turnover by chlorpromazine.

Authors:  M Da Prada; A Pletscher
Journal:  Experientia       Date:  1966-07-15

8.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.

Authors:  M D Yahr; R C Duvoisin; M M Hoehn; M J Schear; R E Barrett
Journal:  Trans Am Neurol Assoc       Date:  1968

9.  The effect of tropolone on the formation of 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the brain of the mouse.

Authors:  G F Murphy; D Robinson; D F Sharman
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

10.  [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease].

Authors:  O HORNYKIEWICZ
Journal:  Wien Klin Wochenschr       Date:  1963-05-03       Impact factor: 1.704
View more
  8 in total

1.  Approaches to the study of cerebral dopamine metabolism in certain extrapyramidal diseases.

Authors:  V P Barkhatova; E I Kandel'; E G Demina
Journal:  Neurosci Behav Physiol       Date:  1985 Mar-Apr

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

4.  The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.

Authors:  S Bergmann; G Curzon; J Friedel; R B Godwin-Austen; C D Marsden; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1974-10       Impact factor: 4.335

5.  Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF.

Authors:  R B Godwin-Austen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-06       Impact factor: 10.154

6.  Effect of folic acid by mouth on cerebrospinal fluid homovanillic acid and 5-hydroxyindoleacetic acid concentration.

Authors:  R Hunter; J Barnes; G Curzon; B D Kantamaneni; C Duncan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-10       Impact factor: 10.154

Review 7.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

Review 8.  Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions.

Authors:  Nadia Magdalinou; Andrew J Lees; Henrik Zetterberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-04-01       Impact factor: 10.154
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.